10 Myths About Sjogren’s Fatigue: A Clinician’s Guide

Fatigue is the leading cause of disability in Sjogren’s, yet it receives remarkably little attention from clinicians and researchers. Addressing this critical unmet need requires clinicians to discard long-standing misconceptions, recognize that fatigue is primarily biological rather than psychological in origin, and routinely evaluate patients for its many underlying causes.  Because even modest improvements can dramatically alter a patient's quality of life, fatigue management must be integrated into standard Sjogren’s care. Backed by medical literature, this post challenges 10 pervasive myths and helps to pave the way for a fresh, evidence-based approach to fatigue management.

This page is part of the Sjogren’s Fatigue For Clinicians series, which is divided into three separate installments for ease of reading:

• Fatigue Fundamentals For Clinicians

• 10 Myths About Sjogren's Fatigue: A Clinician's Guide (this post)

• Assessment and Management (upcoming)

  
  
  
  

Rethinking Sjogren’s Fatigue: 10 Myths Debunked

Myth #1:  Most people with Sjogren’s live normal lives; If fatigue is present, it’s usually mild and benign.

REALITY:   Fatigue is highly prevalent, impacting 70-96% of patients, and is just as much a “hallmark” of Sjogren’s as is sicca. It is often devastating and should never be called benign. Fatigue, not dryness (sicca), is the top reason for reduced quality of life, social participation, and work disability (198, 277, 279).

RESOURCES:  1. The Sjogren’s Foundation Living with Sjogren’s 2025 Patient Survey. Fatigue was named as the symptom having the greatest impact. 

2. NEW CME- Highly Recommend: Optimizing Diagnosis and Care of Sjogren’s Disease: Real World Perspective From Patients and Clinicians. This free online CME released May 15, 2026 from Prime Inc featured a quality of life survey, and found 70% of respondents have 8 or fewer usable hours in a day. “Usable hours” was defined as the daily window where a patient has enough physical and mental energy to engage in productive activities beyond basic self-care.

Myth #2: Sjogren’s fatigue is milder than fatigue seen in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

REALITY:  Sjogren’s fatigue is, on average, more severe than the fatigue experienced by patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) (99, 281). This is driven in part by the high prevalence of autonomic disorders in Sjogren’s, which are estimated to affect 55% of patients (50). These disorders play a major role in their fatigue, cognitive dysfunction, and overall disability.

 Malfunction of the autonomic nervous system causes the body to work much harder to maintain basic functions. Disorders of orthostatic intolerance such as Postural Orthostatic Tachycardia Syndrome (POTS) reduce cerebral blood flow, contributing to orthostatic intolerance, profound fatigue, and cognitive dysfunction. Autonomic disorders are caused by abnormal biology, not by stress, anxiety, deconditioning, or “functional neurological disorder.”

RESOURCES:

Dysautonomia Overview from the Sjogren’s Foundation  

Autonomic Disorders/POTS: Diagnosis, management, and myths. Myth #3: Most patients have a sicca-limited version of the disease; therefore, fatigue should be considered part of a sicca syndrome.

REALITY: Sjogrens is always sytemic. There is no dryness-only version of the disease.

Fatigue is a core systemic feature of Sjogren’s, not a byproduct of sicca. In fact, fatigue and other systemic features often precede the onset of dryness by years. An estimated 20% of patients present without sicca (3, 232). The traditional model framing Sjogren’s as primarily a dryness disease—with only 30-40% of patients developing systemic manifestations—is outdated, inaccurate, and must be discarded.

A large majority of Sjogren’s patients experience systemic (non-sicca) manifestations. This holds true even when using the ESSDAI, a research tool that inherently underestimates the true spectrum and burden of systemic disease (38, 267, 270, 271). When common non-ESSDAI features are factored in, including major contributors to fatigue such as autonomic disorders, cognitive dysfunction, migraines, and gastrointestinal dysmotility (63, 112) systemic involvement is found in nearly 100% of patients.

RESOURCES: 1. User Guide and Handout: Sjogren’s Is More Than “Just Sicca”  Note: Citations 267, 270, and 271 became available after the handout was created and provide strong corroborating evidence.

Myth #4: Fatigue is primarily caused by stress, depression, and anxiety, making Cognitive Behavioral Therapy (CBT) an effective intervention.

REALITY: Fatigue is nearly ubiquitous in Sjogren’s, regardless of the presence of depression or anxiety (27).  Because fatigue is primarily biological in origin; CBT will not treat the causes of fatigue. However, treating the underlying biology often results in improved mood.

Furthermore, there is no dedicated Sjogren’s fatigue-CBT trial with outcome data. Psychological support is important for helping patients cope with severe chronic diseases. However, helping patients cope is not a substitute for treatment.  

RESOURCES: 1. The Major Categories of Fatigue discusses depression-related fatigue.

Myth # 5: Sjogren’s fatigue is usually caused by fibromyalgia, especially in patients with widespread muscle and joint pain. REALITY:   Fibromyalgia is a syndrome not a disease; it is diagnosed based on symptom patterns, rather than underlying mechanisms. In contrast, Sjogren’s is a well-characterized systemic autoimmune disease that directly causes many fibromyalgia-like symptoms, including fatigue and widespread pain. Treatment should focus on the drivers of symtpoms such as immune dysregulation, joint and muscle inflammation, gastrointestinal dysmotility, small fiber polyneuropathy (181), and autonomic disorders.

RESOURCES: 1. Sjogren's Can Look a Lot Like Fibromyalgia explains why the "fibromyalgia" label should be dropped in people with Sjogren's.

Myth #6: Normal inflammatory markers (CRP and ESR) indicate that Sjogren’s is inactive, inflammation is low, and fatigue is not disease related.

REALITY:

C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are non-specific inflammatory markers that are notoriously unreliable indicators of Sjogren’s disease activity, inflammation, or fatigue severity (152). Sjogren’s related inflammation is not routinely detected by CRP or ESR. Normal CRP and ESR measurements should never be used to declare the disease inactive, nor do they rule out Sjogren's as the primary biological driver of a patient's fatigue.

RESOURCES: Learn more about CRP and ESR in Sjogren’s and the intriguing correlation of Sjogren’s fatigue with the downregulation of inflammation:   

Sjogren’s and Inflammation Part I

Sjogren’s and Inflammation Part II

Myth #7: Patients with a low systemic disease burden as measured by the ESSDAI experience less fatigue than patients with high ESSDAI scores.

REALITY: 

The ESSDAI, a research tool used to measure systemic disease activity, does not predict disease severity, fatigue, or quality of life (99). This lack of correlation occurs because the ESSDAI is limited to a select subset of systemic manifestations and excludes many of the key contributors to fatigue, especially neurological (199).

Myth #8: Disease activity and fatigue correlate with anti-SSA antibody (“SSA”) titers.

REALITY: Anti-SSA antibody titers do not correlate with disease activity or severity, nor do they predict flares (197, 254, 267).  Routine monitoring of anti-SSA titers is not recommended, except in specific clinical circumstances such as pregnancy.

Myth # 9:  Fatigue is usually more severe in  SSA-positive patients because SSA-negative patients have a mild, sicca-limited version of the disease.   

REALITY: 

There is no sicca-limited version of Sjogren’s (see Myth #3, above). SSA-negative patients have similar rates of lung disease (192) and, on average, experience more severe fatigue, pain, and reductions in functional status and quality of life than SSA-positive patients (287). This increased burden is driven, in part, by a higher prevalence of neurological, gastrointestinal, and joint involvement in SSA-negid patients (178,184).

RESOURCES:

Do You Have Antibodies?

SSA and Sjogren’s

Myth # 10: There are no treatments for Sjogren’s fatigue other than lifestyle measures.

REALITY: While lifestyle modifications such as dietary changes, optimized sleep, exercise, and stress reduction can provide modest improvment, they are rarely sufficient to manage a symptom that is primarily biological in origin. Instead, clinicians must systematically evaluate each patient for their specific underlying etiologies.

The clinical approach to autonomic fatigue, for example, looks vastly different from treating fatigue caused by interstitial lung disease, migraines, or electrolyte disturbances from Sjogren’s kidney disease.

RESOURCES: The Causes of Sjogren’s Fatigue How My Doctors Monitor Me For Sjogren’s

Fatigue assessment and management will be discussed in an upcoming post.

Please Note: The content on this page is evidence-based, backed by peer-reviewed citations, and tailored specifically for clinicians. Like all Sjogren’s Advocate content, this page is for educational purposes only and does not constitute medical advice.